Related Experiment Video
Updated: Jun 27, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Vancomycin resistance: are there better glycopeptides coming?
1Critical Care Medicine, University of Pittsburgh Medical Center, 602 A Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA. lindenpk@ccm.upmc.edu
Abstract:
The appearance and dissemination of vancomycin resistance among clinically important Gram-positive bacteria was an important watershed in antimicrobial resistance trends that drastically narrows therapeutic options, particularly among the enterococci. Clinical resistance despite apparent susceptibility has also become an increasingly recognized issue with vancomycin treatment of methicillin-resistant Staphylococcus aureus pneumonia and endocarditis, which may be, in part, due to vancomycin-heteroresistant strains. The newly developed glycopeptides telavancin, dalbavancin and oritavancin have superior in vitro activity, enhanced bactericidality and unique pharmacokinetic properties compared with vancomycin and teicoplanin. Current clinical trial data show noninferiority to vancomycin or standard-of-care antistaphylococcal therapy for complicated skin-skin structure infections, and acceptable safety profiles. Although promising, whether or not these new compounds are clinically efficacious for the true therapeutic deficits created by in vitro and clinical vancomycin resistance is yet to be determined.
Insights
Vancomycin resistance in Gram-positive bacteria limits treatment options. New glycopeptides show promise against resistant strains, but their clinical efficacy for vancomycin resistance requires further study.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Vancomycin resistance in Gram-positive bacteria, especially enterococci, presents significant therapeutic challenges.
- Clinical vancomycin treatment failures in Staphylococcus aureus infections may stem from heteroresistance.
- Emerging resistance necessitates novel antimicrobial strategies.
Purpose of the Study:
- To evaluate the in vitro activity, bactericidal properties, and pharmacokinetic profiles of new glycopeptides.
- To assess the clinical efficacy and safety of these novel agents compared to existing therapies.
- To determine the potential of new glycopeptides in addressing vancomycin resistance.
Main Methods:
- In vitro susceptibility testing of new glycopeptides against resistant Gram-positive bacteria.
- Pharmacokinetic and pharmacodynamic analyses of telavancin, dalbavancin, and oritavancin.
- Review of current clinical trial data for complicated skin and skin structure infections.
Main Results:
- Newer glycopeptides exhibit enhanced in vitro activity and bactericidal effects compared to vancomycin.
- Clinical trials indicate noninferiority to vancomycin for specific infections with acceptable safety.
- Unique pharmacokinetic properties differentiate these agents from older glycopeptides.
Conclusions:
- Novel glycopeptides demonstrate improved antimicrobial properties against vancomycin-resistant pathogens.
- Current data suggest comparable efficacy and safety for certain infections, but further investigation is needed.
- The ultimate clinical utility of these agents in overcoming vancomycin resistance remains to be definitively established.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial Protein Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
